Туберкульоз. Адаптована клінічна настанова, заснована на доказах (стр. 110 )

197. Krishnaswami KV, Somasundaram PR, Tripathy SP, Vaidyanathan B et al A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in south India. Tubercle 1981;62(2):103-112.

198. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. International Journal of Tuberculosis ^ Lung Disease 1999;3(12);1073-1080.

199. Moulding TS, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. International Journal of Tuberculosis & Lung Disease 2002;6(4):313-319.

200. Dick J, Lombard C. Shared vision-a health education project designed to enhance adherence to anti­tuberculosis treatment. International Journal of Tuberculosis & Lung Disease 1997;1(2): 181—186.

201. Bock NN, Sales RM, Rogers T, DeVoe B. A spoonful of sugar...: improving adherence to tuberculosis treatment using financial incentives. International Journal of Tuberculosis & Lung Disease 2001 ;5( I ):96-98.

202. Davidson H, Schluger NW, Feldman PH, Valentine DP et al. The effects of increasing incentives on adherence to tuberculosis directly observed therapy. International Journal of Tuberculosis & Lung Disease 2000;4(9):860-865.

203. Barnwell MD, Chitkara R, Lamberta F. Tuberculosis prevention project. Journal of the National Medical Association 1992;84(12):1014-1018.

204. Hovel! MP, Sipan CL, Blumberg FJ, Hofstetter CR el al. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. American Journal of Public Health 2003;93(11):1871-1877,

205. Morisky DE, Malolte CK, Ebin V, Davidson? et al. Behavioral interventions for the control of tuberculosis among adolescents. Public Health Reports 20Ol;l 16(6):568—574.

206. White MC, Tulsky JP, Reilly P, Mcintosh HW et al A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. International Journal of Tuberculosis & Lung Disease 1998;2{6);506-512.

207. Tulsky JP, Hahn JA, Long HL, Chambers DB et al. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. International Journal of Tuberculosis & Lung Disease 2004;8(1):83~91.

208. White MC, Tulsky JP, Goldenson J, Portillo CJ et al Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Archives of Internal Medicine 2002;162{9):1044-1050.

209. British Thoracic Association, A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Journal of Diseases of the Chest 1981;75{2):141-153.

210. Veen J, Raviglione M, Rieder HL, Migliori GB et al. Standardized tuberculosis treatment outcome monitoring in Europe: recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. European Respiratory Journal 1998;12(2):505~510.

211. White VLC, Moore-Gillon J, Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000;55(ll):962-963.

212. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Dug Resistance Surveillance. Geneva: World Health Organization, 2004.

213. Djuretic T, Herbert J, Drobniewski F, Yates M et al. Antibiotic resistant tuberculosis in the United Kingdom:1993-1999. Thorax 2002;57(6}:477^82.

214. Al Jarad N, Parastatides S, Paul EA, Sheldon CD et al Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992. Thorax 1994;49(8):808-83;0,

215. Pritchard AJ, Hayward AC, Monk PN, Neat KR. Risk factors for drug resistant tuberculosis in Leicestershire-poor adherence to treatment remains an important cause of resistance. Epidemiology & Infection 2003;130{3):481-483.

216. Conaty SJ, Hayward AC. Explaining risk factors for drug resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiology & Infection 2004;132:1099-1108.

217. Anastasis D, Pillai G, Rambiritch V, Abdool Karim SS. A retrospective study of human immuno­deficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. International Journal of Tuberculosis & Lung Disease 1997;l(3):220-224.

218. Githui WA, Juma ES, Van Gorkom J, Kibuga D et al Antituberculosis drug resistance surveillance in Kenya, 1995. International Journal of Tuberculosis & Lung Disease I998;2(6):499-505.

219. Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western Cape. South African Medical Journal 1995;85(6):499-504.

220. Wilkinson D, Pillay M, Davies GR, Sturm AW, Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Transactions of the Royal Society of Tropical Medicine & Hygiene 1996;90(6):692-695.

221. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. Journal of the American Medical Association 1997;278(10):833~837.

222. Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset rveillance of Mycobacterium tuberculosis drug resistance sn France, 1995-1997. AZAY Mycobacteria Study Group. International Journal of Tuberculosis & Lung Disease 2000i4(7):665-672.

223. Lambregts-Van Weezenbeek CSB, Jansen HM, Nagelkerke NJD, Van Klingeren B, Veen J, Nationwide surveillance of drug-resistant tuberculosis in the Netherlands: rates, risk factors and treatment outcome, International Journal of Tuberculosis & Lung Disease 1998;2(4):288~295.

224. Heibling P, Altpeter E, Raeber PA, Pfyffer GE, Zellweger rveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link. European Respiratory Journal 20QO;\6{2}:200-202.

225. Sharnia SK, Turaga KK, Balamurugan A, Salia PK et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infection, Genetics 6- Evolution 2003;3(3): 183-188.

226. Salomon N, Perlman DC, Friedmann P, Buchstein S et al Predictors and outcome of multidrug-resistant tuberculosis. Clinical Infectious Diseases 1995;21{5):1245-1252.

227. Goble M, Iseman MD, Madsen LA, Watte D et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine 1993;328(8):527-532.

228. Telzak EE, Sepkowitz K, Alpert P, Mannheinier S et al Multidrug-resistant tuberculosis in patients without HIV infection. New England Journal of Medicine 1995;333( 14):907—911.

229. Herrera D. Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. Morbidity & Mortality Weekly Report 1996;45(16):330-333.

230. Chan ED, Laurel V, Strand MJ, Chan JF et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Respiratory & Critical Care Medicine 2004;169(10): 1103-1109.

231. Narita M, Alonso P, Lauzardo M, Hotlender ES et al Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001;120(2);343-348.

232. Breathnach AS, de Ruiter A, Holdsworth GM, Bateman NT et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. Journal of Hospital Infection 1998;39(2):111-117,

233. Maloney SA, Pearson ML, Gordon MT, Del Castillo R et al. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Annals of Internal Medicine 1995;\22(2}:90~95.

234. Stroud LA, Tokars JI, Grieco MH, Crawford JT et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infection Control & Hospital Epidemiology 1995;16(3): 141-147.

235. Wenger PN, Otten J, Breeden A, Orfas D et al. Control of nosocomical transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995;345(8944):235-240.

236. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM, Isoniazid for preventing tuberculosis in non-HIV infected persons. The Cochrane Library 1999;(1).

237. Girling DJ, Chan SL. A double-blind placebo-controlled clinical trial of three antituberculosis chemopropbylaxis regimens in patients with silicosis in Hong Kong. American Review of Respiratory Disease 1992;145:36-41.

238. Thompson NJ. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial, International Union Against Tuberculosis Committee on Prophylaxis. Bulletin of the World Health Organization 1982;60(4):555-564.

239. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Annals of Internal Medicine 2002;137(8):640-647.

240. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003;123(1):102-106.

241. Leung CC, Law WS, Chang KC, Tarn CM et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003;124(6):2112-2118.